References
  1. Strand LM, Morley PC, Cipolle RJ, et al. Drug related problems: their structure and function. DICP. 1990; 24: 1093e7.
  2. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995; 155: 1949e56.
  3. http://www.un.org/esa/population/publications/worldageing19502050. Assessed 19 September 2011.
  4. Caratozzolo S, Gipponi S, Marengoni A, et al. Potentially serious drug–drug interactions in older patients hospitalized for acute ischemic and hemorrhagic stroke. Eur Neurol. 2016; 76: 161–6.
  5. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007; 5(4): 345–351.
  6. Simonson W, Feinberg JL. Medication-related problems in the elderly: defining the issues and identifying solutions. Drugs Aging. 2005; 22: 559e69.
  7. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: “There’s got to be a happy medium”. JAMA. 2010; 304: 1592e601.
  8. St Peter WL, Wazny LD, Patel UD. New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management. Current opinion in nephrology and hypertension. 2013; 22(6): 656-62.
  9. Guignard B, Bonnabry P, Perrier A, et al. Drug-related problems identification in general internal medicine: the impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015; 26: 399-406.
  10. Theising KM, Fritschle TL, Scholfield AM, et al. Implementation and clinical outcomes of an employer-sponsored, pharmacist-provided medication therapy management program. Pharmacotherapy. 2015; 35(11): e159–63.
  11. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Ass. 2014; 3 (2): e000718.
  12. Ryan R, Santesso N, Lowe D, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev. 2014; 4:CD007768.
  13. American Pharmacists Association and the National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: Core elements of an MTM service model (version 2.0). J Am Pharm Assoc (2003). 2008; (48): 3.
  14. Bluml BM. Definition of medication therapy management: development of professionwide consensus. J Am Pharm Assoc (2003). 2005; 45 (5): 566–572.
  15. Pharmaceutical Care Network Europe Foundation. PCNE Classification for drug related problems version 8.03. 2019. https://www.pcne.org/upload/files/318_PCNE_classification_V8-03.pdf
  16. Stafford AC, Tenni PC, Peterson GM, et al. Drug-related problems identified in medication reviews by Australian pharmacists. Pharm World Sci. 2009; 31(2): 216–23.
  17. Rhalimi M, Rauss A, Housieaux E. Drug-related problems identified during geriatric medication review in the community pharmacy. Int J Clin Pharm. 2018; 40 (1):109–118.
  18. Kwint HF, Faber A, Gussekloo J, et al. The contribution of patient interviews to the identification of drug-related problems in home medication review. J Clin Pharm Ther. 2012; 37 (6):674–680.
  19. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343: 1075–8.
  20. Bleumink GS, Feenstra J, Sturkenboom MC, et al. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003; 63: 525–34.
  21. H.T. Dougall, J. McLay. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 15 (1996), pp. 91-106.
  22. Hsu S, Ton VK, Dominique Ashen M, et al. A clinician’s guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clin Cardiol. 2013; 36(7):383–93.
  23. Ruano-Ravina A, Pena-Gil C, Abu-Assi E, et al. Participation and adherence to cardiac rehabilitation programs. A systematic review. Int J Cardiol. 2016; 223: 436-43.
  24. Amsterdam, Wenger, Brindis, et al. 2014 AHA/ACC Guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014; 130: e344-e426.
  25. O’Gara, Ascheim, Donald E., et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction :a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 127: e362-e425.
  26. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST- segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European heart journal. 2012; 33 (20):2569-619.
  27. Alsabbagh MW, Lemstra M, Eurich D, et al. Pharmacist Intervention in Cardiac Rehabilitation. Journal of cardiopulmonary rehabilitation and prevention. 2012; 32 (6):394-9.
  28. Al-Baghdadi H, Koca Al-Baghdadi Ç, Abdi A, et al. Introducing clinical pharmacy services to cardiovascular clinics at a university hospital in Northern Cyprus. Int J Clin Pharm. 2017; 39 (6):1185–1193.
  29. Chau SH, Jansen AP, van de Ven PM, et al. Clinical medication reviews in elderly patients with polypharmacy: a cross-sectional study on drug-related problems in the Netherlands. Int J Clin Pharm. 2016; 38 (1): 46–53.
  30. Stegemann S, Ecker F, Maio M, et al. Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev. 2010; 9 (4):384–98.
  31. Chan DC, Chen JH, Wen CJ, et al. Effectiveness of the medication safety review clinics for older adults prescribed multiple medications. J Formos Med Assoc. 2014; 113 (2):106–13.
  32. Chan DC, Chen JH, Kuo HK, et al. Drug related problems (DRPs) identified from geriatric medication safety review clinics. Arch Gerontol Geriatr. 2012; 54 (1):168–74.
  33. Salvi F, Marchetti A, D’Angelo F, et al. Adverse drug events as a cause of hospitalization in older adults. Drug Saf. 2012; 35: 29–45.
  34. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly. Drug Saf. 2007; 30: 911–8.
  35. Viktil KK, Blix HS, Moger TA, et al. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007; 63 (2):187–95.
  36. Hsu WT, Shen LJ, Lee CM. Drug-related problems vary with medication category and treatment duration in Taiwanese heart failure outpatients receiving case management. J Formos Med Assoc. 2016; 115 (5):335–342.
  37. Isetts BJ, Schondelmeyer SW, Artz MB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc (2003). 2008; 48 (2):203–211.
  38. Theising KM, Fritschle TL, Scholfield AM, et al. Implementation and Clinical Outcomes of an Employer-Sponsored, Pharmacist-Provided Medication Therapy Management Program. Pharmacotherapy. 2015; 35 (11): e159–e163.
  39. Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2014; 78 (6):1238–1247.
  40. Lin HW, Lin CH, Chang CK, et al. Economic outcomes of pharmacist-physician medication therapy management for polypharmacy elderly: A prospective, randomized, controlled trial. J Formos Med Assoc. 2018; 117 (3):235–243.